Evidence map›Paper›PMID 35973009›Full record

Trial reportCirculation. Cardiovascular interventions2022

Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.

Bernard R Chaitman, Derek D Cyr, Karen P Alexander, Radosław Pracoń, Kevin R Bainey, Anoop Mathew, Anjali Acharya, Dennis F Kunichoff, Jerome L Fleg, Renato D Lopes and 7 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Circulation. Cardiovascular interventions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01985360 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01985360 phase4completednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial

TypeinterventionalSponsorNYU Langone HealthRan2014 to 2020Enrolled777ConditionsCardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial IschemiaArmsCardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention, Lifestyle, Medication
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 4 countries.

Bernard R ChaitmanSaint Louis University School of Medicine, MO (B.R.C.).ORCID 0000-0002-9216-5317
Derek D CyrDuke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).
Karen P AlexanderDuke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).ORCID 0000-0003-4418-1424
Radosław PracońCoronary and Structural Heart Diseases Department, Institute of Cardiology, Mazowieckie, Poland (R.P.).ORCID 0000-0001-7519-0003
Kevin R BaineyMazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada (K.R.B.).ORCID 0000-0002-5458-4617
Anoop MathewMOSC Medical College Hospital, Kolenchery, India (A.M.).ORCID 0000-0002-0302-1419
Anjali AcharyaJacobi Medical Center, Bronx, NY (A.A.).
Dennis F KunichoffHarvard TH Chan School of Public Health, Boston, MA (D.F.K.).
Jerome L FlegNational National Heart Lung and Blood Institute, Bethesda, MD (J.L.F.).
Renato D LopesDuke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).ORCID 0000-0003-2999-4961
Mandeep S SidhuAlbany Medical College, NY (M.S.S.).
Rebecca AnthopolosNYU Grossman School of Medicine (R.A., J.S.H., S.B.).
Frank W RockholdDuke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).ORCID 0000-0003-3732-4765
Gregg W StoneIcahn School of Medicine at Mount Sinai, New York, NY (G.W.S.).ORCID 0000-0002-3416-8210
David J MaronStanford University School of Medicine, CA (D.J.M.).ORCID 0000-0002-4867-8588
Judith S HochmanNYU Grossman School of Medicine (R.A., J.S.H., S.B.).ORCID 0000-0002-5889-5981
Sripal BangaloreNYU Grossman School of Medicine (R.A., J.S.H., S.B.).ORCID 0000-0001-9485-0652
Clinical Research Institute · USNew York University · USAlbany Medical Center Hospital · USIcahn School of Medicine at Mount Sinai · USInstitute of Cardiology · PLJacobi Medical Center · USMalankara Orthodox Syrian Church Medical College Hospital · INMassachusetts Department of Public Health · USNational Heart Lung and Blood Institute · USSaint Louis University · USStanford University · USUniversity of Alberta · CA

Funding

The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA-CKD Trial-CCC-Lead ApplicationU01HL117905 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BANGALORE, SRIPAL · 2013 to 2019
$9.8M
ISCHEMIA-CKD SDCCU01HL117904 · NHLBI · DUKE UNIVERSITY · PI O'BRIEN, SEAN M · 2013 to 2019
$1.5M
NHLBI NIH HHS U01 HL105907NHLBI NIH HHS U01 HL117904NHLBI NIH HHS U01 HL117905
6 · The paper itself

Abstract

backgroundISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarction (MI) compared with a conservative treatment strategy in patients with advanced chronic kidney disease, stable coronary disease, and moderate or severe myocardial ischemia. The cumulative frequency of different MI type after randomization and subsequent prognosis have not been reported.

methodsMI classification was based on the Third Universal Definition for MI. For procedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas the secondary MI definition used cTn (cardiac troponin); both definitions included elevated biomarker-only events with higher thresholds than nonprocedural MIs. The cumulative frequency of MI type according to treatment strategy was determined. The association of MI with subsequent all-cause death and new dialysis initiation was assessed by treating MI as a time-dependent covariate.

resultsThe 3-year incidence of type 1 or 2 MI with the primary MI definition was 11.2% in invasive treatment strategy and 13.6% in conservative treatment strategy (hazard ratio [HR], 0.66 [95% CI, 0.42-1.02]). Procedural MIs were more frequent in invasive treatment strategy and accounted for 9.8% and 28.3% of all MIs with the primary and secondary MI definitions, respectively. Patients had an increased risk of all-cause death after type 1 MI (adjusted HR, 4.35 [95% CI, 2.73-6.93]) and after procedural MI with the primary (adjusted HR, 2.75 [95% CI, 0.99-7.60]) and secondary MI definitions (adjusted HR, 2.91 [95% CI, 1.73-4.88]). Dialysis initiation was increased after a type 1 MI (HR, 6.45 [95% CI, 2.59-16.08]) compared with patients without an MI.

conclusionsIn ISCHEMIA-CKD, the invasive treatment strategy had higher rates of procedural MIs, particularly with the secondary MI definition, and lower rates of type 1 and 2 MIs. Procedural MIs, type 1 MIs, and type 2 MIs were associated with increased risk of subsequent death. Type 1 MI increased the risk of dialysis initiation. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01985360.

Indexed as

Coronary Artery DiseaseMyocardial InfarctionRenal Insufficiency, ChronicBiomarkersHumansIschemiaTreatment OutcomeBiomarkersepidemiologymortalitymyocardial infarctionmyocardial ischemiamyocardial revascularizationrenal insufficiency, chronic

Identifiers

PMID35973009
PMCPMC10865178
OpenAlexW4292003825

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.